Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintaining functional capacity and biomarker stability in ATTR-CM patients.
Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months
Posted inCardiology news

Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months

In ATTRibute‑CM and its open‑label extension, acoramidis (712 mg twice daily) produced consistent reductions in all‑cause mortality and cardiovascular hospitalizations in both wild‑type and variant ATTR cardiomyopathy, including p.Val142Ile, with mortality benefit persisting through month 42.